Laut Analyse könnte der Drogendeal zwischen den USA und Großbritannien in England zu 229.000 zusätzlichen Todesfällen führen | NHS | Der Wächter

I’m sure that’s a price American pharma shareholders are willing to pay.

Starmer desperately sucking up to Trump has gone so well.

In the end Trump was always going to go too far, Starmer would have to put his foot down and all other benefits would be completely wiped out. When Iran happened, Starmer did the right thing and wiped out all his previous efforts to get Trump on his side. 

This was completely obvious always should have been anticipated. That is wasn’t was a total failure of strategic thinking.

Plus, Trump is incapable of gratitude. So it would never have helped anything anyway.

I don’t think Westminster is particular bothered with prioritizing the NHS over the US’s interests. They haven’t even bothered to look into the impact of US based (or companies with a major US stake holder) hoover up GPs.

If this is true, Starmer should have gone a long time ago. This is an extremely bad deal for the UK

Buy the non branded version the rest of the world uses

1. It’s ALL new branded medicines, not just American ones
2. The NICE willingness to pay threshold hasn’t budged in 20 years, and there’s been 20 years worth of inflation in that time
3. The threshold was so low that pharma companies were simply not bothering to pursue UK reimbursement for certain drugs if the price wasn’t high enough
4. The study assumes that the NHS budget won’t increase and that resources have to be re allocated from existing NHS services
5. It’s worth taking anything Karl Claxton says about NICE’s WTP threshold with a massive pinch of salt. Claxton thinks that it should be around £6k rather than £35k per QALY. He’s a great health economist but he clearly has an agenda

We simply weren’t spending enough money on drugs before. The UK has the lowest branded medicine prices in the developed world, but we were starting to lose access to new, innovative treatments because pharma companies had to offer massive discounts to achieve reimbursement, and it often simply wasn’t worth it. Our low WTP threshold was working against us.

This is an incredibly dumb take. It basically boils down to „if you dont give the NHS infinite funding people die“, which I guess is true at some level but also not really feasible.

Yes, we now pay (a bit) more for drugs. But the prior situation was completely unsustainable even before Trump. We were essentially taxing drug companies 50% of *revenue* on drug sales to the NHS (in addition to normal corporation taxes).

No one in the industry or government through that could last. Drug companies were pulling research facilities put of the UK, they were refusing to sell new drugs to the NHS. All of those things would have cost lives (not accounted for in the BMJs ‚research‘).

For anyone who wants to know more just google PPRS and VPAG. Those schemes had been a long running issue and the new settlement is the solution to that issue which everyone seems able to live with.

The bottom line is we pay some of the lowest prices in the world for drugs, and that is still the case, but there are limits to how far you can push it.